We focused on CDHP, because tegafur has antigrowth activity and it is difficult to analyze only antimetastatic activity, and potassium oxonate mainly localizes in gut after oral administration of S‐1 and does not seem to affect the activities of cancer cells generated in other organs. Here, CDH3 is linked to cancer.